Volume : 09, Issue : 05, May – 2022

Title:

45.LIQUID CRYSTALS CONTAINING ACOTIAMIDE CAPSULE FOR ORAL DELIVERY REVIEW

Authors :

Dr. Sandip.R. Pawar, Mr. Jayesh Pratap Patil, Dr. Bharat.V. Jain, Mr. Tanveer.Y. Shaikh

Abstract :

The liquid may be a substance that which is thermodynamically situated in within the middle of the isotropic liquid and also the crystalline phase. They show flow properties sort of a liquid and at the identical time partly hold the order of a crystal. The liquid will be deliberated 1 / 4 states of matter following solid, liquid, and gas. Liquid-crystal phases, as their term suggests, be existing between the expected crystal phase and therefore the liquid phase. Typically, liquid-crystal molecules keep rod-like structure or disc-like anisotropic structures. The distinctive characteristic of liquid crystals is that the propensity of the molecules to support them with long-range direction.
KEYWORDS- Liquid Crystals, Acotiamide, Functional Dyspepsia.

Cite This Article:

Please cite this article in press Jayesh Pratap Patil et al, Liquid Crystals Containing Acotiamide Capsule For Oral Delivery Review., Indo Am. J. P. Sci, 2022; 09(5).,

Number of Downloads : 10

References:

1. ACHOURI, D., ALHANOUT, K., PICCERELLE, P. & ANDRIEU, V. 2013. Recent advances in ocular drug delivery. Drug development and industrial pharmacy, 39, 1599-1617.
2. ALTAN E, MASAOKA T, FARRE R, TACK J. Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome. Expert Rev Gastroenterol Hepatol. 2012;6(5):533–544.
3. SUZUKI H, HIBI T. Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia. Neurogastroenterol Motil. 2010;22(6):595–599.
4. XIAO G, XIE X, FAN J, et al. Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis. ScientificWorldJournal. 2014;2014:1–9.
5. SANGER GJ, ALPERS DH. Development of drugs for gastrointestinal motor disorders: translating science to clinical need. Neurogastroenterol Motil. 2008;20(3):177–184.

6. KUSUNOKI H, HARUMA K, MANABE N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24(6):540–545, e250–e541. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders Gastroenterology. 2006;130(5):1466–1479.
7. UEKI S, MATSUNAGA Y, MATSUMURA T, et al. Z-338, a novel prokinetic agent, stimulates gastrointestinal motor activity and improves delayed gastric emptying in the dog and rat. Naunyn Schmiedebergs Arch Pharmacol.1998;358:R351.
8. OGISHIMA M, KAIBARA M, UEKI S, KURIMOTO T, TANIYAMA K. Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J Pharmacol Exp Ther. 2000;294(1):33–37.
9. SETO K, SASAKI T, KATSUNUMA K, KOBAYASHI N, TANAKA K, TACK J. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil. 2008;20(9):1051–1059.
10. MATSUEDA K, HONGO M, TACK J, AOKI H, SAITO Y, KATO H. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia – 100 mg tid is an optimal dosage. Neurogastroenterol Motil. 2010;22(6):e618–e173.
11. AGARWAL, S., CHINN, L. & ZHANG, L. 2013. An overview of transporter information in package inserts of recently approved new molecular entities. Pharmaceutical research, 30, 899-910.
12. AN, J.-G., HINA, S., YANG, Y., XUE, M. & LIU, Y. 2016. CHARACTERIZATION OF LIQUID CRYSTALS: A LITERATURE REVIEW. Reviews on Advanced Materials Science, 44.
13. ANBARASAN, B., GRACE, X. & SHANMUGANATHAN, S. 2015. An overview of cubosomes—smart drug delivery system. Sri Ramachandra Journal of Medicine, 8, 1-4.
14. BEI, D., MARSZALEK, J. & YOUAN, B.-B. C. 2009. Formulation of dacarbazine-loaded cubosomes—part II: influence of process parameters. AAPS PharmSciTech, 10, 1040.
15. BENSON, D. A., KARSCH-MIZRACHI, I., LIPMAN, D. J., OSTELL, J. & WHEELER, D. L. 2006. GenBank. Nucleic acids research, 34, D16-D20.
16. BULTAS, J. 2013. Antiplatelet therapy—A pharmacologist’s perspective. cor et vasa, 55, e86-e94.
17. CHALIKWAR, S., SHIRKHEDKAR, A., BAGUL, M., JAIN, P. & SURANA, S. 2012. Development and validation of zero and first-order derivative area under curve spectrophotometric methods for the determination of entacapone in bulk material and in tablets. Pharmaceutical methods, 3, 14-17.
18. CHANDRASEKHAR, S. 1993. Discotic liquid crystals. A brief review. Liquid Crystals, 14, 3-14.
19. COLLET, J.-P., SILVAIN, J., BARTHÉLÉMY, O., RANGÉ, G., CAYLA, G., VAN BELLE, E., CUISSET, T., ELHADAD, S., SCHIELE, F. & LHOEST, N. 2014. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. The Lancet, 384, 1577-1585.
20. DIERKING, I. & AL-ZANGANA, S. 2017. Lyotropic liquid crystal phases from anisotropic nanomaterials. Nanomaterials, 7, 305.